Drug Use Evaluation: Newer Antiepileptic Drugs Executive Summary
|
|
- Morris Haynes
- 5 years ago
- Views:
Transcription
1 Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon Phone Fax Drug Use Evaluation: Newer Antiepileptic Drugs Executive Summary Background Newer Antiepileptic Drugs (AEDs) are all approved for the treatment of various seizure disorders, however their use for other mental health and pain conditions has increased, sometimes without strong evidence of effectiveness. The clinical evidence currently does not support the use of the newer AEDs, except lamotrigine which is not covered in this report, for the treatment of bipolar disorder The majority of clinical evidence does not support the use of topiramate or oxcarbazepine for neuropathic pain. No data suggests pregabalin is superior to gabapentin for neuropathic pain. Utilization Analysis The Oregon FFS program spends nearly $1 million quarterly on drugs in the AED class While the use of pregabalin has increased dramatically in the last 2 years, topiramate, levetiracetam, oxcarbazepine, and gabapentin represent the cost centers in this class In 2006, 3367 unique patients used an AED and 50% used at least one drug for at least 90 continuous days (chronic users) Users of gabapentin, carbamazepine, and topiramate made up 2/3 of all chronic AED users More than 1 in 10 (12%) chronic users were documented as receiving two AEDs concurrently Of these patients a small number had documented use of concurrent AEDs that would be considered irrational (pregabalin/gabapentin & oxcarbaepine/carbamazepine) because the drugs are structurally related to each other Diagnostic data suggest that almost 30% were being treated for seizure disorder. Patients using more than one AED were twice as likely to have documented seizure disorder. Roughly 15% of subjects had a diagnosis of neuropathic pain and 6 7% had a diagnosis of bipolar disorder % of chronic users of levetiracetam and zonisamide and 50% of patients using oxcarbazepine were documented to have a seizure disorder Approximately 40% of subjects using topiramate did not have a diagnosis documented Prescriptions written by psychiatry or neurology specialists varied between drugs, with gabapentin having the lowest proportion of specialty prescribing and zonisamide having the largest proportion. Recommendations The College of Pharmacy to develop policy recommendations based on DUR board deliberations
2 Background In addition to their established uses in the treatment of various types of seizure disorders, many of the antiepileptic drugs (AEDs) have been tried for the treatment of bipolar disorder and neuropathic pain. With the exception of lamotrigine, the use of some of the newer AEDs for these indications is often off label and is not well supported by evidence based findings. This literature review will focus on the appropriate use of gabapentin (Neurontin, generics), oxcarbazepine (Trileptal), pregabalin (Lyrica), and topiramate (Topamax) for indications other than seizure disorders. Of the four AEDs, only pregabalin and gabapentin have FDA approved indications for the treatment of neuropathic pain disorders (topiramate is indicated for the treatment of migraine). None of the AEDs are indicated for the treatment of bipolar affective disorder. (Table 1) Table 1. FDA Approved Indications for Certain AEDs FDA Approved Indications Bipolar Affective Pain Disorder Antiepileptic Mania Depression Migraine TGN PHN DPN Drug Gabapentin X Pregabalin X X Topiramate X Oxcarbazepine The Oregon Drug Effectiveness Review Project recently coordinated a systematic review of AED for treatment of bipolar mood disorder, neuropathic pain, and fibromyalgia. 1 The findings of this review are summarized below. Gabapentin (Neurontin, generics) Gabapentin is not indicated nor is it recommended for the treatment of bipolar affective disorder. 2 There is, however, a substantial body of evidence that supports its use in neuropathic pain. In addition, its use is recommended for the treatment of reflex sympathetic dystrophy, complex regional pain syndrome, painful diabetic neuropathy and post herpetic neuralgia by a number of different treatment guidelines. 3,4,5 Most placebo controlled trials of gabapentin in neuropathic pain show evidence of some beneficial effects across different types of neuropathic pain in terms of improvement in symptom rating scores, responder rates, speed of response, duration of response, sleep interference, and certain domains of quality of life questionnaires. 1 Currently there is no evidence to suggest that gabapentin is superior to amitriptyline or carbamazepine. It is, however, an effective alternative. Its number needed to treat (NNT) for any neuropathic pain syndrome is Summary: Gabapentin is not recommended for the treatment of bipolar affective disorder. Its use in various neuropathic pain syndromes is well supported by the literature and several treatment guidelines. Gabapentin is now available as a generic. Pregabalin (Lyrica) Pregabalin is structurally similar to its predecessor gabapentin. There is no evidence available that supports its use in bipolar affective disorder. Available placebo controlled trials of pregabalin in neuropathic pain show evidence of some beneficial effects across different types of neuropathic pain in terms of improvement in symptom rating scores, responder rates, speed of response, duration of response, sleep interference, and certain domains of quality of life questionnaires. 1 Current evidence does not demonstrate clinically significant differences between gabapentin and pregabalin in terms of analgesic efficacy or side effects. 1 Although, some data suggests that pregabalin is more likely to cause adverse effects at higher doses compared to gabapentin. 1
3 Summary: There is no evidence to support the use of pregabalin in bipolar disorder. Evidence suggests that pregabalin is effective for the treatment of neuropathic pain. There is no data that supports its superiority over gabapentin. Topiramate (Topamax) Topiramate is a newer AED indicated for both seizure disorders and the prophylaxis of migraine headaches. Currently available literature demonstrates mixed results in terms of its efficacy in the treatment of pain syndromes. In the majority of studies, topiramate failed to show treatment benefit compared to placebo. 1 Its use in psychiatry has increased both as a mood stabilizer and as a treatment adjunct for the promotion of weight loss. Because weight loss is not a covered diagnosis under the Oregon Health Plan, this review will focus on the evidence supporting its use as a mood stabilizer. Four randomized placebo controlled studies (two with active comparators) examining the use of topiramte as monotherapy for the management of acute mania were available for review after inclusion period for the DERP report. Each of these studies failed to demonstrate topiramate s superiority over placebo. In the two trials using lithium as an active comparator, lithium was statistically significantly superior to topiramate. (Table 2) Table 2. Studies examining topiramate monotherapy for acute mania 6 Study Population Outcome Measure Results PDMD week RCT, vs. PCB, vs. Li YMRS (mean change from baseline) PDMD week RCT, vs. PCB PCB=111 TOP=107 (200mg) TOP=107 (400mg) Li=113 PCB=98 TOP=107 (400mg) TOP=98 (600mg) YMRS (mean change from baseline) PCB = 7.7, TOP 200 = 5.8 (p=0.223) PCB = 7.7, TOP 400 = 6.2 (p=0.324) TOP 200 = 5.8, Li = 12.9 (p<0.001) TOP 400 = 6.2, Li = 12.9 (p<0.001) PCB = 7.7, Li = 12.9 (p=0.001) PCB = 7.7, TOP 400 = 8.2 (p=0.729) PCB = 7.7, TOP 600 = 7.9 (p=0.808) PDMD week RCT, vs. PCB PCB=106 TOP=105 (400mg) YMRS (mean change from baseline) PCB = 6.4, TOP 400 = 5.1 (p=0.263) PDMD week RCT, vs. PCB, vs. Li PCB=112 TOP=115 (400mg) Li=114 YMRS (mean change from baseline) PCB = 8.4, TOP 400 = 8.2 (p=0.976) TOP 400 = 8.2, Li = 13.8 (p<0.001) PCB = 8.4, Li = 13.8 (p<0.001) RCT = Randomized Controlled Trial PCB = Placebo, TOP=Topiramate, Li = Lithium YMRS=Young Mania Rating Scale In another randomized, placebo controlled study reviewing the use of topiramate as an adjunct to valproate or lithium therapy, the authors similarly found that topiramate was no different than placebo in the reduction of the Young Mania Rating Scale (YMRS). 7 Summary: The majority of evidence has failed to demonstrate topiramate s superiority over placebo for the treatment of neuropathic pain. There is no evidence to suggest that topiramate is effective when used alone or in combination with a mood stabilizer for the treatment of Bipolar I Disorder. Oxcarbazepine (Trileptal) Oxcarbazepine is chemically related to its predecessor carbamazepine. Carbamazepine is indicated for the treatment of bipolar affective disorder and certain neuropathic pain syndromes. Currently available
4 literature does not support the use of oxcarbazepine in the treatment of neuropathic pain. The following table presents data from studies available for review after the DERP report. Table 3. Studies evaluating the efficacy of oxcarbazepine in neuropathic pain. Study Population Outcome Measure Results Beydoun et al 8 16 week RCT study vs. PCB Grosskopf et al week RCT study vs. PCB OXC 600mg = 83 OXC 1200mg = 87 OXC 1800mg = 88 PCB = 89 OXC 1200mg = 71 PCB = 70 Primary = VAS Others = GATE, onset of therapeutic effect, durability of treatment effect, sleep disturbances, QOL Primary = VAS Others = GATE, onset of therapeutic effect, durability of treatment effect, sleep disturbances, QOL VAS = NSS improvement over PCB for ITT population. Only 1800mg group showed improvement over PCB in completer analysis in mean VAS score. Other measures = NSS differences compared to PCB VAS = NSS improvement over PCB Other measures = NSS differences compared to PCB RCT = Randomized Controlled Trial PCB = Placebo, OXC = oxcarbazepine VAS = Visual Analog Pain Scale, GATE = Global Assessment of Therapeutic Effect, QOL = Quality of Life NSS = no statistically significant, ITT = Intent to treat Very little data exists that evaluates the use of oxcarbazepine in bipolar affective disorder. The only study with a meaningful number of enrolled patients (n=116) found that oxcarbazepine was not statistically significantly superior to placebo in the treatment of manic symptoms in children and adolescents with bipolar disorder. 10 A systematic review of the available studies determined that additional double blind randomized studies with adequate follow up periods are necessary to determine its place in therapy. 11 Although the data around the use of oxcarbazepine for bipolar patients is limited, it has been clinically viewed as an acceptable alternative to carbamazepine. 12 Summary: Available evidence does not support the use of oxcarbazepine in neuropathic pain syndromes. Also, its place in the treatment of bipolar disorder has not been defined. Methods Trend analysis An AED was defined as topiramate, levetiracetam, oxcarbazepine, gabapentin, pregabalin, carbamazepine, zonisamide, or tiagabine. Using pharmacy claims from between 1/1/05 and 3/21/07, trends in AED costs and utilization were quantified as a monthly per member per month (PMPM) value. Costs were defined as ingredient cost (paid amount + copay amount + other insurance paid dispensing fee) and utilization was defined as the number of prescriptions dispensed. Dual Medicare/Medicaid enrollees were excluded from trend analyses. Finally, total and average costs for 30 days were quantified during the first quarter of 2007 for all enrolled patients. AED User Analysis For calendar year 2006, AED users were identified. For each AED user those with at least 90 consecutive days of therapy (chronic use cohort) were identified using the time interval between the first fill and final fill plus the final fill day supply. In addition, the sum of each patient s day supply for that AED had to be at least 75% of the total interval to ensure a minimum level of adherence. Demographic information such as age, sex, and race were quantified in all AED users as well as the chronic use cohort. From the chronic use cohort the prevalence of patients on more than one AED was characterized. Duplicate AED use was defined as being prescribed two unique AED with a continuous overlap of at least
5 90 days. The prevalence of each unique combination was summarized with specific attention given to irrational combinations such as pregabalin and gabapentin, and carbamazepine and oxcarbazepine. Among all users, chronic users, and duplicate users we characterized the prevalence of diagnoses that may be common for AED users. Specifically, we used ICD9CM codes from medical claims submitted during 2006 to quantify the number of patients with a number of conditions known to be treated with AEDs. Seizure disorder was defined as epilepsy (ICD9CM 345xx), or convulsions (ICD9CM 7803x). Bipolar disorder was defined as bipolar affective disorder (ICD9CM 2964x, 2965x, 2966x, 2967x). Neuropathic pain was defined as disorders of peripheral nervous system (ICD9CM 350x), diabetes with neurological manifestations (ICD9CM 2506x), and Herpes zoster with nervous system complications (ICD9CM 0531x). Additionally, the prevalence of anxiety disorders (ICD9CM 300xx), fibromyalgia (ICD9CM 7291x), and migraine were quantified (ICD9CM 346xx). Finally, we quantified which prescriptions were associated with prescribers with a psychiatry or neurology background. Psychiatry background was defined as being certified as a psychiatrist or child psychiatrist. Neurology was defined as being certified as a neurologist or neuropsychiatrist. Results Trend Analyses From 2005 to 1 st quarter 2007 utilization of AEDs increased 14% and costs increased 21%. Figures 1 and 2 show the PMPM utilization and cost changes occurring for each AED during this period. The summary in table 4 shows the largest increase was observed for pregabalin, which emerged on the market in September 2005 and has experienced a 3 fold increase in growth and cost since. The use and costs of topiramate, levetiracetam, and oxcarbazepine have also grown considerably in this time period. The 52% increase in cost PMPM for oxcarbazepine appears mainly driven by a combination of cost inflation and increased dosing rather than utilization, which was stable throughout the period. Costs PMPM for gabapentin and zonisamide both decreased due to patent expiration and generic drug competition. According to 2007 claims data, Oregon FFS pays nearly $1 million dollars quarterly on these AEDs. Topiramate (38%), levetiracetam (17%), and oxcarbazepine (14%) represent more than 2/3 of this expenditure. Figure 1: AED Utilization (rx dispensed PMPM x1000) 8.0 Rx PMPM (x1000) GABAPENTIN CARBAMAZEPINE TOPIRAMATE LEVETIRACETAM PREGABALIN OXCARBAZEPINE ZONISAMIDE TIAGABINE Mar 07 Jan 07 Nov 06 Sep 06 Jul 06 May 06 Mar 06 Jan 06 Nov 05 Sep 05 Jul 05 May 05 Mar 05 Jan 05
6 Figure 2: Individual (left axis) and total (right axis) AED Costs (Ingredient cost PMPM) Cost PMPM ($) $1.60 $1.40 $1.20 $1.00 $0.80 $0.60 $0.40 $0.20 $4.50 TOPIRAMATE LEVETIRACETAM $4.00 GABAPENTIN OXCARBAZEPINE $3.50 PREGABALIN CARBAMAZEPINE $3.00 ZONISAMIDE $2.50 TIAGABINE HCL Total $2.00 $1.50 $1.00 $0.50 $0.00 $0.00 Mar 07 Jan 07 Nov 06 Sep 06 Jul 06 May 06 Mar 06 Jan 06 Nov 05 Sep 05 Jul 05 May 05 Mar 05 Jan 05 Table 4: Oregon FFS AED trend summary and ingredient Costs and average Cost / 30 days 1 st Quarter 2007 % Change 2005 to 2007 First Quarter 2007 Costs Drug PMPM utilization PMPM cost Total Cost % Average Cost / 30 days TOPIRAMATE (TOPAMAX) 18.9% 32.2% $346,063 (37.7%) $280 LEVETIRACETAM (KEPPRA) 28.9% 50.2% $158,092 (17.2%) $269 OXCARBAZEPINE (TRILEPTAL) 0.0% 51.6% $127,339 (13.9%) $246 GABAPENTIN (NEURONTIN, generics) 1.5% 32.4% $116,861 (12.7%) $79 PREGABALIN (LYRICA) 279.3% 301.5% $76,701 (8.4%) $144 CARBAMAZEPINE (TEGRETOL, TEGRETOL XL, generics) 7.2% 4.0% $64,017 (7.0%) $50 ZONISAMIDE (ZONEGRAN, generics) 1.8% 56.0% $17,558 (1.9%) $87 TIAGABINE (GABITRIL) 54.5% 12.4% $10,238 (1.1%) $209 Total 13.7% 21.4% $916,869 $156 AED User Analysis A total of 3367 unique FFS patients had at least one fill for an AED drug in 2006, of which 1689 (50%) were considered a chronic user of an AED. The demographics, shown in table 5, suggest that the two groups were similar in terms of measurable patient characteristics. The average age was 35 years, however the range was from the very young (<1) to the very old (90). Racial and gender breakdown are consistent with overall population characteristics.
7 Table 5: Demographics of all AED users and chronic users 2006 All Users Chronic Users n=3367 n=1689 Age Mean Range < Female 2137 (63.5%) 1028 (60.9%) Race White 2944 (87.4%) 1503 (89.0%) Hispanic 135 (4.0%) 61 (3.6%) American Indian 130 (3.9%) 51 (3.0%) Black 73 (2.2%) 32 (1.9%) Asian 34 (1.0%) 18 (1.1%) other 51 (1.5%) 24 (1.4%) The plurality of chronic AED users were taking gabapentin (31%), followed by carbamazepine (26%), and topiramate (25%). Table 6 summarizes the distribution of specific AED use as well as the prevalence of any AED duplication and specific irrational duplications. Approximately 12% of all chronic users used 2 different AEDs concurrently for at least 90 days. Twenty two patients, (11% of all duplicate users) were identified as using either gabapentin and pregabalin or carbamazepine and oxcarbazepine together. Table 6: Distribution of AED users among chronic users (>=90 days continuous therapy) 2006 Drug n=1689 GABAPENTIN 529 (31.3%) CARBAMAZEPINE 443 (26.2%) TOPIRAMATE 418 (24.7%) OXCARBAZEPINE 206 (12.2%) PREGABALIN 195 (11.5%) LEVETIRACETAM 185 (11.0%) ZONISAMIDE 65 (3.8%) TIAGABINE 28 (1.7%) Duplicate Therapy 199 (11.8%) % of pregabalin patients also on gabapentin 13 (6.7%) % of oxcarbazepine patients also on carbamazepine 9 (4.4%) Table 7 shows the breakdown of every AED combination. The more common duplications include topiramate with carbamazepine, gabapentin, and levetiracetam; and carbamazpine with levetiracetam. However, the overall number of subjects on duplicate AEDs was small. Table 8 summarizes the prevalence of specific diagnoses which are commonly treated, both on and offlabel, with AEDs. In general, the prevalence of diagnoses among all users and chronic users were similar. Between 46% and 53% of AED users had at least one diagnosis for a disease of interest. Roughly 1/3 of subjects had a diagnosis indicating a seizure disorder. 6 7% of patients had a diagnosis of bipolar disorder and 15 16% had a diagnosis code indicating neuropathic pain. When the cohort was restricted to only the 199 patients who received duplicate AEDs, the prevalence of seizure disorder doubled to nearly 60% while the other two remained relatively unchanged or decreased. The prevalence of migraine and anxiety disorder was approximately 10%. Table 9 summarizes the prevalence of specific diagnoses among chronic drug users by drug. These data indicate that 73 81% of use for zonisamide
8 Table 7: Prevalence of concurrent combinations among chronic users (n=1689) 2006 ZONISAMIDE CARBAMAZEPINE GABAPENTIN LEVETIRACETAM n CARBAMAZEPINE 11 (17.7%) 24 (4.8%) 30 (17.8%) 9 (4.6%) 7 (4.6%) 2 (8.0%) 35 (8.9%) GABAPENTIN 2 (3.2%) 24 (5.7%) 5 (3.0%) 5 (2.6%) 13 (8.6%) 1 (4.0%) 23 (5.8%) LEVETIRACETAM 8 (12.9%) 30 (7.1%) 5 (1.0%) 10 (5.2%) 8 (5.3%) 2 (8.0%) 29 (7.3%) OXCARBAZEPINE 3 (4.8%) 9 (2.1%) 5 (1.0%) 10 (5.9%) 3 (2.0%) 0 (0.0%) 11 (2.8%) PREGABALIN 2 (3.2%) 7 (1.7%) 13 (2.6%) 8 (4.7%) 3 (1.5%) 0 (0.0%) 11 (2.8%) TIAGABINE 0 (0.0%) 2 (0.5%) 1 (0.2%) 2 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) TOPIRAMATE 4 (6.5%) 35 (8.3%) 23 (4.6%) 29 (17.2%) 11 (5.7%) 11 (7.2%) 0 (0.0%) ZONISAMIDE 11 (2.6%) 2 (0.4%) 8 (4.7%) 3 (1.5%) 2 (1.3%) 0 (0.0%) 4 (1.0%) OXCARBAZEPINE PREGABALIN TIAGABINE TOPIRAMATE Table 8: Diagnostic information of all, chronic and concurrent AED users 2006 All Users >=90 Days Therapy Duplicate therapy n seizure disorder 917 (27.2%) 581 (34.4%) 114 (57.3%) bipolar disorder 246 (7.3%) 107 (6.3%) 8 (4.0%) neuropathic pain 517 (15.4%) 273 (16.2%) 26 (13.1%) migraine 341 (10.1%) 133 (7.9%) 18 (9.0%) anxiety disorder 383 (11.4%) 164 (9.7%) 11 (5.5%) fibromyalgia 201 (6.0%) 89 (5.3%) 11 (5.5%) any of above 2020 (60.0%) 1065 (63.1%) 149 (74.9%)
9 Table 9: Diagnostic information for chronic AED users by drug 2006 TOPIRAMATE TIAGABINE PREGABALIN OXCARBAZEPINE LEVETIRACETAM GABAPENTIN CARBAMAZEPINE ZONISAMIDE n seizure disorder 72.6% 61.6% 16.3% 80.5% 45.4% 19.1% 20.0% 31.9% bipolar disorder 3.2% 5.7% 4.8% 1.2% 11.9% 6.6% 12.0% 8.6% neuropathic pain 3.2% 6.2% 35.9% 4.1% 5.2% 48.0% 12.0% 10.6% migraine 1.6% 2.8% 7.2% 2.4% 3.1% 8.6% 12.0% 19.5% anxiety disorder 8.1% 5.7% 10.8% 4.1% 8.2% 13.2% 8.0% 12.2% fibromyalgia 4.8% 1.4% 7.8% 0.6% 1.5% 15.1% 4.0% 6.1% any of above 79.0% 68.5% 58.4% 75.7% 61.9% 67.1% 48.0% 63.5% Table 10: Prescribed by clinician with psychiatry or neurology certification ZONISAMIDE TOPIRAMATE TIAGABINE PREGABALIN OXCARBAZEPINE LEVETIRACETAM GABAPENTIN CARBAMAZEPINE All Use 30.9% 7.5% 47.4% 38.3% 11.8% 23.8% 30.5% 56.2% Chronic Use 34.4% 9.0% 51.5% 41.2% 15.1% 24.0% 36.7% 59.7%
10 and levetiracetam may be for treating a seizure disorder. Nearly 50% of subjects using oxcarbazepine were documented with seizure disorder. Between 36 48% of gabapentin and pregabalin use is among subjects with a neuropathic pain diagnosis. The prevalence of migraine was highest among topiramate users at 20%. About 40% of topiramate users did not have a diagnosis for an approved or commonly used off label condition. Finally, table 10 shows the proportion of all users and chronic users who were prescribed an AED by a physician certified in either psychiatry or neurology. Patients using zonisamide and levetiracetam comprised the largest proportion of specialty prescribing among the studied AEDs. Conclusion and Recommendations Antiepileptic drugs are a costly and growing class of drugs. The use of AEDs for non evidenced based conditions is concerning because of previous experience with gabapentin. While gabapentin and pregabalin are FDA approved and have demonstrated effectiveness for select neuropathic pain conditions, data do not support the use of topiramate or oxcarbazepine for this condition. Similarily, the use of AEDs, except for lamotrigine, for bipolar affective disorder is not supported in the literature. Analysis of pharmacy and medical claims indicate the seizure disorder remains the predominate diagnosis for all studied AEDs except gabapentin and pregabalin where diagnoses of neuropathic pain are common. Bipolar and anxiety disorders appear to be the treated condition in a small proportion of subjects ranging from 6 10%. 1 Goodman F, Glassman P, Maglione M. Drug Class Review on Antiepileptic Drugs in Bipolar Mood Disorder, Neuropathic Pain, and Fibromyalgia Available at: ttp:// Accessed May 15, Anonymous. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004;38(5): Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60(11): Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes. A national clinical guideline. Scottish Intercollegiate Guidelines Network (SIGN). Edinburgh, Scotland Anonymous. Washington Department of Labor and Industries, Washington State Medical Association. Guideline for the use of Neurontin in the management of neuropathic pain. Seattle (WA): Washington Department of Labor and Industries, Washington State Medical Association; Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: results of four double blind placebo controlled trials. Bipolar Dis. 2006;8: Chengappa R, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patient receiving a mood stabilizer for bipolar I disorder: a randomized, placebo controlled trial. J Clin Psychiatry. 2006;67(11): Beydoun A, Shairbani A, Hopwood M, et al. Oxcarbazepine in painful diabetic neuropathy: results of a doseranging study. Acta Neurol Scand. 2006;113: Grosskopf J, Mazzola J, Wan Y, et al. A randomized, placebo controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand. 2006;114: Wagner KD, Kowatch RA, Emslie GJ, et al. A double blind, randomized, placebo controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry. 2006;163: Mazza M, Di Nicola M, Martinotti G, et al. Oxcarbazepine in bipolar disorder: a critical review of the literature. Expert Opin Pharmacother. 2007;8: American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar affective disorder. 2nd edition Available at: Accessed May 15, 2007.
Epilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society
Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate
More informationGeneric Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationNew Patient Questionnaire - Epilepsy
New Patient Questionnaire - Epilepsy Person completing this form: (if other than the patient) GENERAL SEIZURE HISTORY Relationship: When do you think your child had their first seizure? When was the last
More informationRefractory epilepsy: treatment with new antiepileptic drugs
Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: ERX.NPA.10 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationPharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers
Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationMedications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
More informationPolicy Evaluation: Low Dose Quetiapine Safety Edit
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4
More informationDepakote for pain management
P ford residence southampton, ny Depakote for pain management Cancer patients often experience significant pain. Sometimes this is a side effect of the treatment, and sometimes because of the cancer itself.
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the
More informationPlacebo Response in Chronic Pain: What Have We Learned
Placebo Response in Chronic Pain: What Have We Learned John T. Farrar, MD, PhD Departments of Epidemiology Neurology and Anesthesia Senior Scholar Center for Clinical Epidemiology and Biostatistics University
More informationAnticonvulsant Prior Authorization Request
Anticonvulsant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More informationFINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19
1 FINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19 Prescription Utilization Patterns and Hospitalizations in Epilepsy Patients on Anti Epileptic Drugs Abraham G. Hartzema,
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationeslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd
eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationLyrica. Lyrica (pregabalin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Lyrica Page: 1 of 6 Last Review Date: June 22, 2017 Lyrica Description Lyrica (pregabalin)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Lacosamide (Vimpat) Reference Number: CP.PMN.155 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationExecutive Summary Pregabalin (Lyrica by Pfizer) Formulary Review
Executive Summary Pregabalin (Lyrica by Pfizer) Formulary Review Lyrica (pregabalin) is a new prescription medication indicated for use in painful diabetic peripheral neuropathy (DPN), post-herpetic neuralgia,
More information7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia
Directorate of Integrated Care Health and Social Care Board 12-22 Linenhall Street Belfast BT2 8BS Tel : 028 90553782 Fax : 028 90553622 Web Site: www.hscboard.hscni.net 7 th November 2013 Dear colleague
More informationDrug Use Evaluation: Low Dose Quetiapine
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationReview of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP
Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic
More information5.9. Rehabilitation to Improve Central Pain
5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...
More informationlevetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines
More informationTable A: Summary of FDA and European Commission Guidance for Industry for Adverse Drug Reaction reporting in product information documents
Table A: Summary of FDA and European Commission Guidance for Industry for Adverse Drug Reaction reporting in product information documents Food and Drug Administration. Guidance for Industry Adverse Reactions
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationNon-Opioid Drugs to Treat Neuropathic Pain. March 2018
Non-Opioid Drugs to Treat Neuropathic Pain Final Report March 2018 This report is intended only for state employees in states participating in the Drug Effectiveness Review Project (DERP). Do not distribute
More informationAntiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol
Market DC Antiepileptics Override(s) Approval Duration Prior Authorization 1 year Step Therapy Quantity Limit *Indiana Medicaid See State Specific Mandate below *Maryland Medicaid See State Specific Mandate
More informationNeurontin drug class. Search
Neurontin drug class Search Neurontin is an anti-epileptic drug, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some. Is Gabapentin
More informationPrescribing and Monitoring Anti-Epileptic Drugs
Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University
More informationClinical Policy: Pregabalin (Lyrica) Reference Number: LA.PMN.33 Effective Date: Last Review Date: 07.18
Clinical Policy: (Lyrica) Reference Number: LA.PMN.33 Effective Date: 01.01.07 Last Review Date: 07.18 Line of Business:Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationClinical Policy: Pregabalin (Lyrica) Reference Number: CP.CPA.68 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Lyrica) Reference Number: CP.CPA.68 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationModified release drug delivery system for antiepileptic drug (Formulation development and evaluation).
TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized
More informationNational Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationFigure 1: Quantity Dispensed/100 Members (Ambien and Sonata on left axis)
Sedative Hypnotic Quantity Limit Policy Impact Analysis Effective 12/6/2 OMAP implemented a 15 tablet per 3 day quantity limit on non-barbiturate sedative hypnotics for FFS patients. This policy was made
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationLYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS
Volume 20, Issue 7 April 2005 LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS Tanja Lepir, Pharm.D. Candidate Nervous system dysfunction leading to neuropathic pain can occur from many causes: infection,
More informationObjectives / Learning Targets: The learner who successfully completes this lesson will be able to demonstrate understanding of the following concepts:
Boone County Fire District EMS Education-Paramedic Program EMS 270 Medical Cases-Seizures Resources Seizures screencast Seizures Flowchart and Seizures Flowchart Video Explanation Objectives / Learning
More informationClinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAuthor: Gibler/Ketchum Date: March 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSeizure medications An overview
Seizure medications An overview Andrew Zillgitt, DO Staff Neurologist Comprehensive Epilepsy Center Department of Neurology Henry Ford Hospital None Disclosures Objectives A lot to review!!!!! Look at
More informationManagement of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse
Management of Epilepsy in Primary Care and the Community Carrie Burke, Epilepsy Specialist Nurse Epilepsy & Seizures Epilepsy is a common neurological disorder characterised by recurring seizures (NICE,
More informationA Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults
FORMULARY MANAGEMENT A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults NALIN PAYAKACHAT, MS; KENT H. SUMMERS, RPh, PhD; and JOHN P.
More informationBEYOND DEMENTIA: WHAT EVERYONE SHOULD KNOW ABOUT MENTAL HEALTH IN THE ELDERLY:
BEYOND DEMENTIA: WHAT EVERYONE SHOULD KNOW ABOUT MENTAL HEALTH IN THE ELDERLY: Beyond Managing Behavior Delivering Accurate & Effective Mental Healthcare MARSHALL, PARKER & WEBER, LLC 2016-20 TH ANNUAL
More informationEfficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy
Special Article Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Absence seizures, 6 in childhood, 95 Adults, seizures and status epilepticus in, management of, 34 35 with first-time seizures. See Seizure(s),
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationDrug Use Research & Management Program Phone Fax Generic Bioequivalency Review of Antiepileptic Drugs and Immunosuppressants
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301 Phone 503-947-5220 Fax 503-947-1119 Generic Bioequivalency Review of Antiepileptic
More information11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova
EPILEPSY UPDATE Dr.Ram Sankaraneni Disclosures Speaker bureau LivaNova 1 Outline New onset Seizure Investigations in patients with epilepsy Medical management of epilepsy Non Pharmacological options in
More informationChapter 31-Epilepsy 1. public accountant, and has begun treatment with lamotrigine. In which of the following activities
Chapter 31-Epilepsy 1 Chapter 31. Epilepsy, Self-Assessment Questions 1. BW is a 28-year-old man recently diagnosed with partial seizures. He works as a certified public accountant, and has begun treatment
More informationAntiepileptics for Indications Other than Epilepsy. March 2009
Antiepileptics for Indications Other than Epilepsy March 2009 Produced by: The Health Resources Commission Office for Oregon Health Policy & Research 1225 Ferry Street SE Salem, OR 97301 Phone: 503.373.1629
More informationIn clinical studies, gabapentin efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day (1-3).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.17 Subject: Gabapentin Page: 1 of 6 Last Review Date: June 22, 2017 Gabapentin Description Gabapentin
More informationMedication use tendencies
Health Promoting psychotropic medication use in persons with autism Ruth Myers MD ruthmmyers@yahoo.com Medication use tendencies Large quantities of unmonitored supplements Medications used in ways they
More informationIntegrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year. Risk of seizures associated with Ranolazine (Ranexa)
Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year Risk of seizures associated with Ranolazine (Ranexa) Efe Eworuke, PhD Division of Epidemiology Office of Pharmacovigilance
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationNew Medicines Profile
New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationANTIEPILEPTIC Medicines
ANTIEPILEPTIC Medicines Treatment with antiepileptic medicines currently enables over 70% of people with epilepsy to live free of seizures. In the last few days years several new medicines have become
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationThe Role of Pregabalin in Fibromyalgia
The Role of Pregabalin in Fibromyalgia Sofia Exarchou Resident at Internal Medicine and Rheumatology at the University Hospital of Skåne, Malmö-Lund Metsovo Greece 2011 History Gowers 1904 Hench 1976 Smythe
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2004-12 Program Prior Authorization/Medical Necessity - Multisource Brand/Modified Release Anticonvulsants Medication/Therapeutic
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2004-10 Program Prior Authorization/Medical Necessity - Multisource Brand/Modified Release Anticonvulsants Medication/Therapeutic
More informationOHSU Drug Effectiveness Review Project Summary Report Non-Opioid Drugs to Treat Neuropathic Pain
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEpilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance
Epilepsy: pharmacological treatment by seizure type Clinical audit tool Implementing NICE guidance 2012 NICE clinical guideline 137 Clinical audit tool: Epilepsy (2012) Page 1 of 25 This clinical audit
More informationScottish Medicines Consortium
Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More information1. Developed: June Revised: November 2017; September 2015; December 2013; January 2012; December 2011; April 2010; August 2006.
Texas Vendor Drug Program Drug Use Criteria: Gabapentin Publication History 1. Developed: June 2006 2. Revised: November 2017; September 2015; December 2013; January 2012; December 2011; April 2010; August
More informationUpdated advice for nurses who care for patients with epilepsy
NICE BULLETIN Updated advice for nurses who care for patients with epilepsy NICE provided the content for this booklet which is independent of any company or product advertised NICE BULLETIN Updated advice
More informationNew Drug Evaluation: brivaracetam [tablet and solution, oral; solution, intravenous]
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTHE SPECIALIST NURSE INTERVENTION: PROMOTING UNDERSTANDING. Marianne Peachey Epilepsy Specialist Nurse The Ipswich Hospital NHS Trust
THE SPECIALIST NURSE INTERVENTION: PROMOTING UNDERSTANDING Epilepsy Specialist Nurse The Ipswich Hospital NHS Trust NURSING Is it Art or Science? Hospital Consultants General Practitioners Hospital Nursing
More informationInteractions between Antiepileptics and Second- Generation Antipsychotics
University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 3-2012 Interactions between Antiepileptics and Second- Generation Antipsychotics Jose de Leon University of Kentucky, jdeleon@uky.edu
More informationSelf Report Seizure Survey Summary 2017
Self Report Seizure Survey Summary 2017 Tetrasomy 18p 61 responses 33 had at least one seizure = 54% 8 had a seizure in the last year Valproate (Depakote) 7 Valproate (Depakote, Epilium) 2 Lamotrigene
More informationSeizures (epilepsy) and brain tumours - treatment
Seizures (epilepsy) and brain tumours - treatment Seizures are the most common first (onset) symptom that leads to a brain tumour diagnosis in adults. Many people with brain tumours develop seizures later
More informationGabapentin to treat hot flashes
P ford residence southampton, ny Gabapentin to treat hot flashes 6-10-2010 An extendedrelease version of the seizure and pain drug gabapentin may be one step closer to becoming the first approved nonhormonal
More informationEpilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview
: Clinical presentation and management Markus Reuber Professor of Clinical Neurology Academic Neurology Unit University of Sheffield, Royal Hallamshire Hospital. Is it epilepsy? Overview Common attack
More informationTRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 LYRICA 25 mg capsules Pack of 56 capsules (CIP: 365 127-0) Pack of 84 capsules (CIP: 365 135-3) Pack of
More informationGeodon for anxiety and depression
When drugs like carbamazepine or cisapride are taken with Geodon, drug interactions can potentially occur. This emedtv page lists other drugs that may lead to Geodon. 8-2-2017 Find a comprehensive guide
More informationCarisoprodolol Quantity Limit Policy Impact Analysis
Carisoprodolol Quantity Limit Policy Impact Analysis Carisoprodolol (Soma ) is a skeletal muscle relaxant that has deemed by many to have limited effectiveness for the treatment of acute musculoskeletal
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3019-9 Program Step Therapy Medication Lyrica capsules, Lyrica Solution, Lyrica CR tablets* (pregabalin) P&T Approval Date 1/08,
More informationPROCEEDINGS PHARMACOLOGIC TREATMENT CONSIDERATIONS * Dennis J. Dlugos, MD ABSTRACT
PHARMACOLOGIC TREATMENT CONSIDERATIONS * Dennis J. Dlugos, MD ABSTRACT A number of traditional and newer antiepileptic drugs (AEDs) are used for the initial treatment of new-onset epilepsy. The decision-making
More informationPharmacological Treatment of Non-Lesional Epilepsy December 8, 2013
Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Michael Privitera, MD Professor of Neurology University of Cincinnati, Neuroscience Institute American Epilepsy Society Annual Meeting
More informationGabapentin (Neurontin) is a medication that was developed as a treatment for neuropathic pain and as an adjunct for seizures.
23-6-2015 Gabapentin (Neurontin) is a medication that was developed as a treatment for neuropathic pain and as an adjunct for seizures. It is also commonly. Common Questions and Answers about Gabapentin
More informationDr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE
Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 262 Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationExecutive Summary. Classes Under Review: Analysis:
Outcome Report on MHQAC Edits Classes Under Review: Analysis: Atypical Antipsychotics, SSRIs, SNRIs, Antianxietals, Hypnotics, and Drugs to Treat ADD/ADHD Utilization and Cost Trends: Pre and Post Implementation
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationManagement of Pain related to Spinal Cord Lesion
Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of
More informationLyrica. Lyrica, Lyrica CR (pregabalin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Page: 1 of 7 Last Review Date: March 16, 2018 Description, CR (pregabalin) Background
More informationEpilepsy and EEG in Clinical Practice
Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Epilepsy: It is the commonest neurological condition, characterized by recurrent seizures, affecting people of all ages, race
More information